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This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocite-
mie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO
classification for the diagnosis of the Philadelphia chromosome-negative myeloproliferative neoplasms.
A series of 103 bone marrow biopsy samples of Philadelphia chromosome-negative myeloproliferative
neoplasms consecutively collected in 2004 were classified according to the WHO criteria as follows: essential
thrombocythaemia (n¼ 34), primary myelofibrosis (n¼ 44) and polycythaemia vera (n¼ 25). Two independent
groups of pathologists reviewed the bone marrow biopsies. The first group was asked to reach a collegial
‘consensus’ diagnosis. The second group reviewed individually all the cases to recognize the main
morphological parameters indicated by the WHO classification and report their results in a database.
They were subsequently instructed to individually build a ‘personal’ diagnosis of myeloproliferative neoplasms
subtype just assembling the parameters collected in the database. Our results indicate that high levels
of agreement (Z70%) have been reached for about all of the morphological features. Moreover, among
the 18 evaluated histological features, 11 resulted statistically more useful for the differential diagnosis among
the different Philadelphia chromosome-negative myeloproliferative neoplasms. Finally, we found a high
percentage of agreement (76%) between the ‘personal’ and ‘consensus’ diagnosis (Cohen’s kappa statistic
40.40). In conclusion, our results support the use of the histological criteria proposed by the WHO
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classification for the Philadelphia chromosome-negative myeloproliferative neoplasms to ensure a more
precise and early diagnosis for these patients.
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Since the introduction of the WHO classification
criteria for the diagnosis of Philadelphia chromo-
some-negative chronic myeloproliferative disorders
in 2001, much emphasis has been put on the
bone marrow histological analysis as an irreplace-
able tool for the diagnosis of these neoplasms.1
Such criteria, stemming from the seminal work
of leading experts,2–5 established the boundaries
among the different pathological entities classified
as Philadelphia chromosome-negative chronic
myeloproliferative disorders, providing indications
on the morphological features to be associated with
clinical and laboratory data in order to achieve a
definite and reproducible diagnosis. The WHO
classification criteria, revised in 2008, by means of
incorporating recent molecular achievements,
underscored the importance of an integrated
approach in which the fine morphology has a
central role.6,7 Prototypical is the example of
megakaryocytes, whose degree of atypia, pro-
liferation and aggregation, have been considered
the pillars of the differential diagnosis of these
disorders. On the other hand, the frequent imple-
mentation of blood counts in routine clinical
practice implies an increasingly early diagnosis
and certainly contributes to the occurrence of
Philadelphia chromosome-negative myeloprolife-
rative neoplasms cases with markedly overlapping
clinical and pathological features, which could
hamper a clear-cut classification. These cases,
regarded as ‘unclassifiable’ in the WHO classi-
fication, account for 10–15% of all myeloprolifera-
tive neoplasms and constitute a diagnostic ‘grey
zone’ virtually linking all the Philadelphia chromo-
some-negative myeloproliferative neoplasms. Most
of the diagnosis of myeloproliferative neoplasms
‘unclassifiable’ derive by the impossibility to reach a
conclusive diagnosis in the presence of clinical or
morphological features that, according to the
WHO classification, are borderline with different
myeloproliferative neoplasms. Recently, the repro-
ducibility of histopathology of bone marrow accord-
ing to WHO classification and its usefulness for
identifying different myeloproliferative neoplasms
has been questioned,8–10 and subsequent contro-
versies between supporters and opponents have
been raised in this setting.
Provided that the correct classification of myelo-
proliferative disorders integrates clinical, molecular
and pathological data, in this study, through the
morphological analysis of bone marrow biopsy
samples of a large series of Philadelphia chromo-
some-negative chronic myeloproliferative neo-
plasms at diagnosis, we aimed to test the inter-
observer reproducibility of the histological para-
meters indicated in the WHO classification and
propose a rational approach to the analysis of these
variables in the differential diagnosis of myelopro-
liferative neoplasms.
Materials and methods
A series of 113 patients from four Institutions
(Milano, Bologna, Reggio Emilia, Palermo) referring
to the Italian Registry of Thrombocythaemias
(Registro Italiano Trombocitemie, RIT) were collected
for the study. Consecutive patients, with newly
diagnosed Philadelphia chromosome-negative mye-
loproliferative neoplasms, fulfilling the WHO classi-
fication criteria and diagnosed in 2004 were included
in this study; this choice was made in order to have a
reliable clinical follow-up. All of the patients signed
their informed consent. As our aim focused on the
differential diagnosis among Philadelphia chromo-
some-negative myeloproliferative neoplasms, cases
with advanced bone marrow fibrosis (MF-3 according
to the European consensus grading system for
marrow fibrosis11) on the basis of the local
diagnosis were excluded from the study. For each
patient, bone marrow biopsy specimen at diagnosis
was available and stained with hematoxylin–eosin,
Giemsa and Gomori’s silver impregnation.
Two groups of pathologists reviewed all the cases.
The first group composed by eight pathologists (UG,
CT, MP, AMF, GFO, SA, EBon, VF) centrally reviewed
the cases and reached a ‘consensus’ diagnosis at a
multi-headed microscope based on the morphologi-
cal analysis and the complete knowledge of the
clinical data. Only cases for which a 100% agree-
ment was reached were included in this study.
A total of 103 out of 113 cases were selected and
classified as follows: essential thrombocythaemia:
n¼ 34, primary myelofibrosis: n¼ 44 (myelofibrosis
grade 0: n¼ 15, myelofibrosis grade 1: n¼ 16,
myelofibrosis grade 2: n¼ 13) and polycythaemia
vera: n¼ 25 (all in the polycythaemic phase of the
disease). Ten cases were excluded from the study
because of the inadequacy of the material (n¼ 6) or
because they have been classified as myeloproli-
ferative neoplasm ‘unclassifiable’ (n¼ 2) and as pre-
polycythaemic phase of polycythaemia vera (n¼ 2).
Table 1 summarizes the most important clinical data
of the study population.
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The second group of four pathologists (ES, EBov,
AM, RV) were asked to review individually all the
103 selected cases, in a blinded fashion, without any
knowledge of the ‘consensus’ diagnosis made by
the first group and of the clinical data, with the
exception of the patient’s age. Their aim was to
recognize and register the main morphological para-
meters included in the WHO classification for each
case and report their results in a database. To carry
out this task, each reviewer received by mail the
same box containing the original slides evaluated by
the first panel of pathologists and a histological form
reporting the list of the morphological features with
minimal explanation on how to compile it, as
reported in the following paragraphs.
The following 18 morphological variables were
examined: (1) overall bone marrow cellularity in
relation to patient’s age; (2) amount of erythropoiesis;
(3) left-shifting erythropoiesis; (4) amount of granulo-
poiesis; (5) left-shifting granulopoiesis; (6) myeloid to
erythroid ratio; (7) amount of megakaryocytes;
(8) loose clusters of megakaryocytes, defined as aggre-
gation of Z3 megakaryocytes, albeit not in reciprocal
contact; (9) dense clusters of megakaryocytes, defined
as aggregation of Z3 megakaryocytes in reciprocal
contact; (10) pleomorphism of the clusters of mega-
karyocytes, defined as the presence of a cluster ofZ3
megakaryocytes of variable size, ranging from small to
giant; (11) small megakaryocytes; (12) giant megaka-
ryocytes (13) megakaryocyte nuclear hyperlobulation
(‘stag horn-like’ morphology); (14) megakaryocyte
bulbous nuclei (‘cloudy-like’ or ‘balloon-shaped’
morphology); (15) megakaryocyte naked nuclei; (16)
megakaryocyte maturation defect defined as nuclear-
to-cytoplasmic ratio alteration; (17) megakaryocyte
nuclear dysmorphism (hyperchromatic and dys-
morphic nuclei); and (18) entity of marrow fibrosis,
(determined according to the European consensus
grading system for marrow fibrosis11). The four
reviewers were instructed to classify the quantitative
morphological variables (numbered 1, 2, 4, 6, 7) with
three possible categories (‘reduced’, ‘normal’ or
‘increased’) and the qualitative variables (numbered
3, 5, 8–18) with two (‘absent’ or ‘present’).12 To register
a qualitative variable as ‘present’, the reviewer had
to identify that specific morphological features at
least two times in the same slide.
Figure 1 represents some of these morphological
features.
In order to assess how morphology alone could
help to reach the correct diagnosis, the four
reviewers were subsequently asked to propose a
‘personal’ diagnosis by just analyzing and assem-
bling the data collected in their databases, without
reviewing the case under the microscope.
Statistical Analysis
To investigate the relationship between morpholo-
gical profile of each case, ‘personal’ and ‘consensus’
diagnosis, we performed a multiple correspondence
analysis. This is a data analysis technique for
categorical data, used to detect and represent under-
lying structures in a data set. It achieves the results
by representing data as points in a low-dimensional
Euclidean space. In this study, we only considered
the first two axes. As a final result of multiple
correspondence analysis, a two-dimensional map
was produced where diagnoses, reviewers and
category of each morphological feature were repre-
sented as points. The degree of accuracy of the map
is given by the percentage of total variance repre-
sented on the two axes of the map. In Figure 2, the
percentage of variance explained by the two axes is
about 91% (horizontal axis: 63.5%; vertical axis:
27.7%).
Cohen’s kappa statistic was used to express the
agreement between the ‘personal’ diagnosis made by
each reviewer and ‘consensus’ diagnosis.
Asymptotic 95% confidence intervals for kappa
statistic were computed according to Fleiss et al.13
A kappa of 0 means that the agreement is no better
than that expected by chance alone, and kappa
values of 1.00 indicate perfect agreement. By
convention, a kappa between 0.81 and 1.00 is
interpreted as indicating excellent agreement. Va-
lues of o0.20, 0.21–0.40, 0.41–0.60 and 0.61–0.80
are interpreted as showing poor, fair, moderate and
good agreement, respectively.14 All data processing
and analyses were carried out with the SAS
statistical software (version 9.2; SAS Institute,
Cary, NC, USA).
Results
Agreement Among the Reviewers on the
Morphological Features
Table 2 shows the percentage of patients for whom
at least 3 out 4 reviewers have classified in the same
way each category of the 18 morphological variable
considered. We found that high levels of crude
agreement (Z70%) have been reached for all of
the morphological features, with the exception of
the presence of naked nuclei (65%). Interestingly,
Table 1 Clinical data of the study population
ET
(n¼ 34)
PMF
(n¼ 44)
PV
(n¼ 25)
Female 50% 60% 44%
Male 50% 40% 56%
Median age 56 years
(21–80)
68 years
(39–93)
65 years
(54–82)
Haemoglobin416.5 g/dl — — 100%
Haemoglobino12 g/dl 10% 34% —
White blood cells count412  109/l 5% 15% 10%
Anaemia and leukocytosis — 5% —
Increased spleen size — 62% 30%
Elevated lactate deidrogenase 10% 61% 70%
Leukoerythroblastic blood picture — 52% 16%
JAK2V617F mutation 54% 55% 92%
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Figure 1 (a) A case of polycythaemia vera with prominent left-shifting erythropoiesis (Giemsa, 40). (b) Dense cluster of
megakaryocytes sometimes with bulbous nuclei are evident in this case of primary myelofibrosis (Giemsa, 20). (c) Large-to-giant
megakaryocytes with hyperlobulated nuclei in a case of essential thrombocythaemia (H&E,  20). (d) A pleomorphic cluster of
megakaryocytes is evident in a case of polycythaemia vera (H&E, 20).
Modern Pathology (2014) 27, 814–822
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the percentage of crude agreement varied among
reviewers in relation to the specific disease: eg,
considering the bone marrow cellularity, the per-
centage of agreement among reviewers was higher in
cases of primary myelofibrosis and polycythaemia
vera (93% and 92%, respectively) than in essential
thrombocythaemia (83%); focusing on the myeloid-
to-erythroid ratio, the percentage of agreement was
higher in essential thrombocythaemia or primary
myelofibrosis (about 80%) than in polycythaemia
vera (40%). Moreover, agreement among reviewers
also varied in relation to the different category of
each single morphological variable: eg, considering
bone marrow cellularity, the percentage of
agreement in primary myelofibrosis ranged from
84% when ‘increased’ to 9% if ‘normal’; focusing
on the myeloid-to-erythroid ratio, in cases of
essential thrombocythaemia the percentage of
agreement varied from 71% when normal to 9% if
increased.
Relationship and Agreement Between Morphological
Features and ‘Consensus’ Diagnosis
To calculate the relationship between the revie-
wers’ evaluations on each morphological variable
and ‘consensus’ diagnosis, we selected a subset of
11 morphological features that had turned out the
most statistically useful for the differential diagnosis
among the three myeloproliferative neoplasms.
The 11 morphological variables selected for all
further analysis were the following: overall bone
marrow cellularity, amount and left-shifting ery-
thropoiesis, amount and left-shifting granulopoiesis,
myeloid-to-erythroid ratio, dense clusters of mega-
karyocytes, pleomorphic clusters of megakaryo-
cytes, hyperlobulation or bulbous appearance of
the nuclei and the grading of marrow fibrosis.
Figures 2a–k shows the graphs obtained by the
multiple correspondence analysis. To allow an easy
reading of the graphs, the 11 morphological features
were reproduced separately, and the reader should
only consider the distance between the points
and their positions on the plane identified by the
first two axes. The horizontal axis contrasts the
morphological profiles of the patients affected by
essential thrombocythaemia vs those by primary
myelofibrosis while the vertical axis contrasts
polycythaemia vera vs essential thrombocythaemia
and primary myelofibrosis. The more different are
the morphological profiles that characterize the
diagnoses, the higher is the distance between the
points that represent the three diagnoses. Along
with this line, the higher is the agreement between
reviewers for each morphological features, the lower
is the distance between the points that represent
them. If a category of a morphological feature and a
particular diagnosis are plotted nearby, this means
that such a morphological parameter is typical of
that particular diagnosis.
Figure 2 Two dimension graphical representation of Multiple
Correspondence Analysis. The horizontal axis contrasts the
morphological profiles of essential thrombocythaemia (ET)
patients vs those with primary myelofibrosis (PMF), while the
vertical axis contrasts polycythaemia vera (PV) vs ET and PMF.
Quantitative variables (~¼ reduced, m¼normal, ’¼ increased)
and qualitative variables (n¼ absent, m¼present) are re-
presented.
Modern Pathology (2014) 27, 814–822
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Results reported in Figures 2a–k can be summar-
ized as follows: (1a) bone marrow cellularity: we
found a good agreement among reviewers when it
was regarded as ‘normal’ or ‘increased’. As expected,
the ‘normal’ category was more frequently associated
by the four reviewers to essential thrombocythaemia;
(1b) amount of erythropoiesis: a good agreement has
been found when erythropoiesis increases and this
category has been more frequently associated to
polycythaemia vera cases; (1c) left-shifting erythro-
poiesis: a good agreement has been found when this
category was ‘absent’ and this modality do not
support a diagnosis of polycythaemia vera; (1d)
amount of granulopoiesis: a moderate agreement has
been reached when ‘normal’ or ‘increased’ and lack
agreement when ‘reduced’. Normal granulopoiesis
resulted more frequently associated with essential
thrombocythaemia, while increased granulopoiesis
with primary myelofibrosis; (1e) left-shifting granu-
lopoiesis: good agreement has been reached when
‘absent’ and this category was more frequently
observed in essential thrombocythaemia; (1f) mye-
loid-to-erythroid ratio: a good agreement has been
reached when increased and this appeared more
frequent in primary mielofibrosis, while only a
moderate agreement when ‘normal’ (more frequently
associated with essential thrombocythaemia) or
‘reduced’ (more frequently associated with poly-
cythaemia vera); (1g) dense clusters of megakaryo-
cytes: good agreement was reported when ‘absent
‘and moderate-to-good agreement when ‘present’.
Presence of dense clusters of megakaryocytes has
Table 2 Absolute number (n) and percentage (%) of patients for whom at least 3 out 4 reviewers have classified in the same way each
category of the 18 morphological variable
Total
(n¼ 103)
Essential
thrombocythaemia (n¼ 34)
Primary myelofibrosis
(n¼ 44)
Polycythaemia vera
(n¼25)
Morphological variable Category n (%) n (%) n (%) n (%)
Bone marrow cellularity Normal 27 (26) 22 (65) 4 (9) 1 (4.0)
Increased 65 (63) 6 (18) 37 (84) 22 (88.0)
Amount of erythropoiesis Reduced 5 ( 5) — 5 (11) —
Normal 49 (48) 28 (82) 19 (43) 2 (8)
Increased 19 (18) — 2 ( 5) 17 (68)
Left-shifting erythropoiesis Absent 79 (77) 33 (97) 44 (91) 6 (24)
Present 13 (13) 1 ( 3) — 12 (48)
Amount of granulopoiesis Reduced 0 ( 0.0) — — —
Normal 34 (33) 25 (74) 5 (11) 4 (16)
Increased 50 (49) 4 (12) 35 (80) 11 (44)
Left-shifting granulopoiesis Absent 46 (45) 30 (88) 7 (16) 9 (36)
Present 33 (32) 4 (12) 21 (48) 8 (32)
Myeloid /erythroid Reduced 2 ( 2) — — 2 ( 8)
Normal 33 (32) 24 (71) 2 (5) 7 (28)
Increased 37 (36) 3 (9) 33 (75) 1 ( 4)
Amount of megakaryocytes Normal — — — —
Increased 103 (100) 34 (100) 44 (100) 25 (100)
Loose clusters of megakaryocytes Absent 1 (1) — 1 ( 2) —
Present 97 (94) 34 (100) 39 (89) 24 (96)
Dense clusters of megakaryocytes Absent 59 (57) 29 (85) 12 (27) 18 (72)
Present 28 (27) 1 ( 3) 23 (52) 4 (16)
Pleomorphism of the clusters of
megakaryocytes
Absent 74 (72) 30 (88) 39 (87) 5 (20)
Present 15 (15) 1 ( 3) 2 ( 5) 12 (48)
Small megakaryocytes Absent 9 ( 9) 6 (18) 3 ( 7) —
Present 69 (67) 14 (41) 36 (82) 19 (76)
Giant megakaryocytes Absent 3 ( 3) — 3 ( 7) —
Present 89 (86) 34 (100) 34 (77) 21 (84)
Hyperlobulation nuclei of
megakaryocytes
Absent 31 (30) 2 ( 6) 24 (55) 5 (20)
Present 54 (52) 31 ((91) 12 (27) 11 (44)
Bulbous nuclei of megakaryocytes Absent 30 (29) 26 (77) 1 ( 2) 3 (12)
Present 49 (48) 4 (12) 32 (73) 13 (52)
Naked nuclei Absent 33 (32) 16 (47) 7 (16) 10 (40)
Present 34 (33) 4 (12) 26 (59) 4 (16)
Maturation defects Absent 14 (14) 9 (27) 2 ( 5) 3 (12)
Present 61 (59) 12 (35) 36 (82) 13 (52)
Dysmorphic (hypercromatic) nuclei Absent 52 (51) 24 (71) 13 (30) 15 (60)
Present 26 (25) 3 ( 9) 20 (46) 3 (12)
Grade of marrow fibrosis MF-0 58 (56) 30 (88) 13 (30) 15 (60)
MF-1 16 (16) 3 ( 9) 9 (21) 4 (16)
MF-2 11 (11) — 11 (25) —
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been observed more frequently in primary myelofi-
brosis; (1h) pleomorphic clusters of megakaryocytes:
a good agreement was found when ‘absent’ and this
modality do not support the diagnosis of poly-
cythaemia vera; (1l) hyperlobulated nuclei of mega-
karyocytes: moderate agreement was reached for
both the absent or present categories; (1j) bulbous
nuclei of megakaryocytes: good agreement was
reached when present (more frequent in primary
myelofibrosis); and (1k) grade of marrow fibrosis:
good agreement was found in grade 0 and in grade 2,
while moderate agreement in grade 1.
Agreement Among ‘Personal’ and ‘Consensus’
Diagnosis
Focusing on the 11 selected morphological features,
we further investigated if a morphological analysis
alone was sufficient per se to reach a correct
diagnosis of Philadelphia chromosome-negative
myeloproliferative neoplasms even in the absence
of clinical data.
We calculated the percentage of crude agreement
between the ‘personal’ diagnosis and ‘consensus’
diagnosis. A case has been considered classified
(agreement reached) when at least three out four
reviewers made the same ‘personal’ diagnosis
corresponding to the ‘consensus’ one. We found
that morphology alone allow to correctly classify
72% of the cases (Table 3).
Moreover, we calculated the agreement between
‘personal’ diagnosis of each of the four reviewers
and ‘consensus’ diagnosis. The results indicate a
higher percentage of crude agreement ranging from
65 to 84% (mean value: 76%), with moderate-to-
good values of Cohen’s kappa statistic (ranging from
0.41 to 0.80) (Table 4).
Discussion
The classification of Philadelphia chromosome-
negative myeloproliferative neoplasms is a challen-
ging task because of the potential clinical and
pathogenic overlap at onset among the different
diseases, which clearly reflects on the lack of
pathognomonic morphological features; equally im-
portant, most bone marrow biopsies are presently
performed earlier than in the past in almost
‘asymptomatic’ patients, whose abnormalities are
mostly restricted to peripheral blood count values,
such as thrombocytosis.15–18 In this study, aimed to
evaluate the inter-observer reproducibility of the
morphological parameters considered for the
diagnosis of Philadelphia chromosome-negative
myeloproliferative neoplasms, we found an overall
high level of agreement (470%) for about all these
features. Interestingly, the percentage of agreement
ranged among reviewers in relation to the individual
pathological entity and to the different categories of
each morphological feature. It is important to note
that our study is the only one which analyzes the
inter-observer reproducibility of the morphological
criteria of the WHO classification considering all the
three Philadelphia chromosome-negative myelo-
proliferative neoplasms. We think that this
approach could better reproduce the daily clinical
practice.
WHO classification of myeloproliferative neo-
plasms has been considered as poorly reproducible
by some groups, while others managed to reach
satisfactory interobservers’ agreement; even in this
latter event, a variable degree of morphologically
unclassifiable cases were always recorded.8,9,17–19
This issue is not trivial, especially considering
some recent reports, in which the prognostic impact
of histology is reached when a central pathology
review is asked to experts such as the authors of the
WHO chapter on MPN classification.20–23
Although the current classification per se enabled
to reach inconceivable achievements, the above-
reported controversies disclose some drawbacks of
this classification scheme of MPN.
In the present study, the lowest scores were
obtained when reviewers considered myeloid-to-
erythroid ratio (70%) and the presence of naked
nuclei (65%), with the former reaching the highest
discordance in polycythaemia vera cases. Discor-
dance in the evaluation of the myeloid-to-erythroid
ratio, particularly in PV cases, can be understood as
this ratio can vary from either normal, if the two
lineages increase consistently, or decreased if ery-
thropoiesis is more increased than granulopoiesis.
However, as it is relevant for a diagnosis, the use
of myeloid- and erythroid-associated markers could
be suggested, either always or only in cases of
uncertainty. Alternatively, the simultaneous evalua-
tion of bone marrow biopsy and aspirate smears can
allow an accurate estimation of the erythroid and
myeloid series and their quantification. Moreover,
some degree of discordance, and particularly about
erythropoiesis, may be attributed to the variable
quality of different staining. To this regard, here we
like to underline that optimally treated bone marrow
Table 3 Crude agreement between ‘personal’ and ‘consensus’ diagnosis
Essential thrombocythaemia (n¼34) Primary myelofibrosis (n¼ 44) Polycythaemia vera (n¼25) Total (n¼103)
Classified 20 (59%) 39 (89%) 15 (60%) 74 (72%)
Not classified 14 (41%) 5 (11%) 10 (40%) 29 (28%)
A case has been considered classified (agreement reached) when at least 3 out 4 reviewers made the same ‘personal’ diagnosis corresponding to
the ‘consensus’ one.
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biopsies and good quality slides and staining are
mandatory prerequisites for the best possible diag-
noses and that Giemsa staining can help in the
evaluation of erythropoiesis and granulopoiesis. At a
variance with the other groups,18 the concordance
about the ‘loose cluster’ parameter is very high
(95%), but it did not bear significance in differen-
tiating the three myeloproliferative neoplasms.
Moreover, we selected 11 out of 18 morphological
features that resulted the most statistically useful for
the differential diagnosis among the three myelo-
proliferative neoplasms. Our analysis demonstrated
that these selected parameters allow to correctly
classify 72% of the cases by morphology alone.
Interestingly, primary myelofibrosis is the disease
for which the highest level (89%) of consensus has
been reached.
To further investigate the relationship between
morphological profiles identified by four reviewers
and ‘consensus’ diagnosis, we performed a multiple
correspondence analysis on the 11 selected vari-
ables. Analysis of the results in Figure 2 can help to
identify the more useful parameters in the diagnosis
of a myeloproliferative neoplasms; (a) cellularity:
this parameter, if normal for the patient’s age, seems
crucial in the diagnostic pathway as all reviewers
associated it with a diagnosis of essential thrombo-
cythaemia; (b) increased amount of erythropoiesis
and left shifting: when present, these were critical
parameters as all reviewers associated them with a
diagnosis of polycythaemia vera; (c) increased
amount of granulopoiesis and left shifting: their
occurrence are useful to rule out a diagnosis of
essential thrombocythaemia; and (d) dense clusters
of megakaryocytes: this parameter is clearly useful,
because its presence is strongly suggestive for
primary myelofibrosis. However, as dense clusters
are infrequent, particularly in early-onset cases of
PMF, it appears advisable to evaluate additional
serial sections in order to increase the chance to
detect them; (e) bulbous nuclei of megakaryocytes:
when evident they suggest a diagnosis of primary
myelofibrosis; (f) reticulin fibers: as expected, the
presence of significant fibrosis frankly addresses the
diagnosis towards primary myelofibrosis.
Although these figures do not allow us to design
an independent histological diagnostic flow chart, it
should be taken into account that some morpholo-
gical parameters (such as cellularity, amount/shift-
ing of erythropoiesis and granulopoiesis) could be
more helpful than others in reaching the correct
diagnosis.
The putative critical diagnostic role played by
megakacaryocytes deserves to be slightly re-shaped.
In fact, when the WHO classification 2001 was publi-
shed, the concept that primary myelofibrosis was
composed exclusively of bulbous megakaryocytes,
while essential thrombocythaemia was represented
almost by stag-horn ones was prevalent. Our daily
experience actually suggests that megakaryocytes in
these diseases are not so monomorphic and such a
degree of morphological variability is always encoun-
tered, along with the presence of elements with
additional morphological properties, including small
elements, naked nuclei and maturation defects. The
attempt should thus be to discover the typical ones in
the whole biopsy setting, and this could be difficult
particularly in early stage diseases.
Finally, to assess impact of subjectivity in the
‘personal’ diagnosis, we compared it with the
‘consensus’ diagnosis. Our results indicate an over-
all median percentage of crude agreement of 76%
between the ‘personal’ diagnosis of each reviewers
and ‘consensus’ diagnosis, with moderate-to-good
values of Cohen’s kappa statistic. These positive
results certainly reflect the different experience
among the four reviewers, but at the same time they
confirm that it is possible to reach high levels of
agreement and suggest that better results could
probably be obtained by means of specific training.
Taken together, these findings suggest that even if
morphology alone allows the classification of most
of the cases, integration with clinical and molecular
data is mandatory for a correct classification of
myeloproliferative neoplasms as indicated by the
WHO classification.
In conclusion, the present study demonstrates
that high levels of agreement could be reached
among pathologists in recognizing the morphologi-
cal features indicated by the WHO classification of
Philadelphia chromosome-negative myeloprolifera-
tive neoplasms. Although this success reinforces the
reproducibility of these histological parameters,
about one-third of the cases of myeloproliferative
neoplasms could not be efficiently classified by
morphological examination alone. Notwithstanding
these limitations, bone marrow histology should
always be performed in the diagnostic work-up of
myeloproliferative neoplasms, as individual para-
meters (in particular represented by overall cellu-
larity, amount/shifting of erythropoiesis and granu-
lopoiesis and bone marrow fibrosis) may be helpful
in the differential diagnosis of Philadelphia chro-
mosome-negative myeloproliferative neoplasms or
have prognostic significance.24,25 Keeping this in
mind, and without entering into the logic of
supporting or opposing the WHO classification, we
believe that these promising results deserve to be
Table 4 Percentage of crude agreement and Cohen’s kappa
statistic (with 95% confidence interval) between ‘personal’
diagnosis of each reviewer and ‘consensus’ diagnosis
Personal diagnosis vs consensus diagnosis
Reviewers (n¼103) Kappa IC95%
1 73% 0.58 0.46–0.72
2 84% 0.76 0.65–0.87
3 83% 0.73 0.62–0.84
4 65% 0.46 0.32–0.59
mean 76%
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further improved, possibly with the organization of
larger consensus conferences, to ensure a more
precise and early diagnosis for patients affected by
these dramatic diseases.
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